From Single Targets to Systems Biology: A New Framework for Neurodegenerative R&D For three decades, neurodegeneration programmes have been built around a tightly focused premise: find the toxic protein, clear it from the brain, protect the vulnerable neuron. Alzheimer’s was framed as an amyloid and tau problem. Parkinson’s as a dopamine and alpha-synuclein problem. ALS as a motor neuron problem. That framing has driven real progress – from disease-modifying antibodies to g

When you talk to leaders who make it to GM, franchise head, or the C‑suite in pharma and biotech, a different pattern shows up: sideways moves into new functions, therapeutic areas, or business models that didn’t look like promotions at the time, but turned out to be pivotal.

GLP‑1 weight‑loss drugs started as diabetes medicines. Now they’re quietly becoming one of the most powerful tools in obesity treatment — and they’re still evolving. The science is advancing quickly. The harder question is whether access, cost, and policy will keep up.

For generations, treating cancer has relied on a pretty brutal calculus: hit the body hard and hope the cancer dies first. Traditional chemotherapy is essentially a scorched-earth strategy. It works, but at a massive cost—wrecking the heart, gut, and nervous system along with the tumour. . For decades, researchers have chased a deceptively simple question: What if we could send the drug only where it’s actually needed? Antibody-drug conjugates, or ADCs, are the most promising